Iradimed Corp logo


Iradimed Corp


Earnings Summary

Net Profits
Net Profit Margins
PE Ratio



Iradimed Corp’s revenue jumped 29.67% since last year same period to $12.72Mn in the Q2 2022. On a quarterly growth basis, Iradimed Corp has generated 3.34% jump in its revenue since last 3-months.

Net Profits:

Iradimed Corp’s net profit jumped 120.53% since last year same period to $3.24Mn in the Q2 2022. On a quarterly growth basis, Iradimed Corp has generated 30.33% jump in its net profits since last 3-months.

Net Profit Margins:

Iradimed Corp’s net profit margin jumped 70.06% since last year same period to 25.48% in the Q2 2022. On a quarterly growth basis, Iradimed Corp has generated 26.13% jump in its net profit margins since last 3-months.

PE Ratio:

Iradimed Corp’s price-to-earnings ratio after this Q2 2022 earnings stands at 38.08.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Iradimed Corp post its latest quarter earnings

EPS Estimate Current Quarter
EPS Estimate Current Year


EPS Estimate Current Quarter:

Iradimed Corp’s earning per share (EPS) estimates for the current quarter stand at 0.24 - a 14.29% jump from last quarter’s estimates.

EPS Estimate Current Year:

Iradimed Corp’s earning per share (EPS) estimates for the current year stand at 0.24.

Key Ratios

Key ratios of the Iradimed Corp post its Q2 2022 earnings

Earning Per Share (EPS)
Return on Assets (ROA)
Return on Equity (ROE)
Dividend Per Share (DPS)


Earning Per Share (EPS):

Iradimed Corp’s earning per share (EPS) jumped 85.71% since last year same period to 0.26 in the Q2 2022. This indicates that the Iradimed Corp has generated 85.71% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Iradimed Corp’s return on assets (ROA) stands at 0.11.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Iradimed Corp’s return on equity (ROE) stands at 0.19.

Dividend Per Share (DPS):

Iradimed Corp declared 0 dividend per share during the earnings announcement for Q2 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %

Company Information

IRADIMED CORPORATION is a leader in the development of innovative magnetic resonance imaging ('MRI') compatible medical devices. It's the only known provider of a non-magnetic intravenous ('IV') infusion pump system that is specifically designed to be safe for use during MRI procedures. The Company is the first to develop an infusion delivery system that largely eliminates many of the dangers and problems present during MRI procedures. Standard infusion pumps contain magnetic and electronic components which can create radio frequency interference and are dangerous to operate in the presence of the powerful magnet that drives an MRI system. Its patented MRidium® MRI compatible IV infusion pump system has been designed with a non-magnetic ultrasonic motor, uniquely-designed non-ferrous parts and other special features to safely and predictably deliver anesthesia and other IV fluids during various MRI procedures. Its pump solution provides a seamless approach that enables accurate, safe and dependable fluid delivery before, during and after an MRI scan, which is important to critically-ill patients who cannot be removed from their vital medications, and children and infants who must generally be sedated to remain immobile during an MRI scan.

Iradimed Corp
Winter Springs, Florida, US
Health Technology
Leslie McDonnell